Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06223568
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 45
- Registration Number
- NCT06217757
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 378
- Registration Number
- NCT06212752
- Locations
- 🇯🇵
Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan
🇯🇵Fujita Health University ( Site 4406), Toyoake, Aichi, Japan
🇯🇵Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-01-17
- Target Recruit Count
- 268
- Registration Number
- NCT06208826
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Drug Screening Using IMD in Bladder Cancer
- Conditions
- Interventions
- Device: Implantable Micro-DeviceDrug: MethotrexateDrug: CarboplatinDrug: AvelumabDrug: PaclitaxelDrug: VinblastineDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: CisplatinDrug: NivolumabDrug: PembrolizumabDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: ErdafitinibDrug: Paclitaxel/Docetaxel/IfosfamideDrug: GemcitabineDrug: Gemcitabine/Carboplatin/NivolumabDrug: EnfortumabDrug: Sacituzumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 35
- Registration Number
- NCT06181032
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 46
- Registration Number
- NCT06170697
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT06162221
- Locations
- 🇺🇸
Cancer Specialists of North Florida, St Augustine, Florida, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇩🇪Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg, Germany
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.